GAITHERSBURG, Md., Oct. 11, 2023 /PRNewswire/ -- Novavax, Inc.
(Nasdaq: NVAX), a global company advancing protein-based vaccines
with its Matrix-M™ adjuvant, will present study findings during two
posters sessions at IDWeek 2023, October
11-15, and three oral presentations at World Vaccine
Congress (WVC) Europe
2023, October 16-19. Highlights include clinical data on
Novavax's BA.1, BA.5 and bivalent variant vaccines, an evaluation
of its prototype COVID-19 vaccine in children aged 6 to 11 years,
real-world evidence on adverse events post-COVID vaccination and an
update on its COVID-19-Influenza Combination (CIC) vaccine
candidate.
"We are excited to share the latest clinical data and real-world
evidence advancing the science behind our protein-based vaccine
technology," said Filip Dubovsky,
MD, President of Research and Development, Novavax. "These data
will support the expansion of our label and describe
characteristics that may help drive vaccine choice."
At IDWeek, Novavax will present data on key COVID-19 vaccine
attributes that drive people's vaccine choices, and clinical data
from two studies comparing its Omicron BA.1 and BA.5 variant
vaccines to its prototype COVID-19 vaccine's ability to induce
superior neutralizing antibody responses to BA.1 and BA.5 viruses
in individuals previously vaccinated with mRNA vaccines.
At WVC EU, Novavax will showcase data from its Vaccine Impact on
Productivity real-world study investigating the burden and impact
of vaccine reactogenicity (solicited adverse local/systemic side
effects), its Phase 2b/3 Hummingbird™
global clinical trial evaluating its prototype vaccine in children
aged six through 11 years as well as its CIC vaccine candidate.
Novavax poster presentations during
IDWeek:
|
Author
|
Presentation
title
|
Details
|
|
Rousculp, M
|
Results From the
COVID-19
Vaccines Discrete Choice
Experiment Pre-Test Qualitative
Interviews in Canada, Germany, the
UK, and US General Population
|
Poster
Presentation
October 13,
2023
12:15-13:30pm
(EST)
BCEC Poster Hall
Poster: 1371
|
|
Bennett, C
|
Immunogenicity and
Safety of a
Heterologous Booster Dose
of Omicron Subvariant (BA.1 and BA.5)
and Bivalent SARS-CoV-2
Recombinant Spike Protein
Vaccines: A Phase 3, Randomized,
Clinical Trial
|
Poster
Presentation
October 14,
2023
12:15-13:30pm
(EST)
BCEC Poster Hall
Poster: 2337
|
Novavax oral presentations during WVC EU:
|
Author
|
Presentation
title
|
Details
|
|
Zatonski,
M
|
Hummingbird NVX-CoV2373
COVID-
19 Global Clinical Trial: Data for
Children 6 through 11 Years of Age
|
Oral
Presentation
October 17,
2023
13:45pm
(CET)
Room 4
|
|
Shinde,
V
|
Update on Novavax
Investigational
Influenza vaccine and COVID-19-Influenza
Combination Vaccine Development
|
Oral
Presentation
October 18,
2023
14:00pm
(CET)
Room 4
|
|
Perretti, A
|
COVID-19 Vaccines in
the Real
World: Observed Reactogenicity
Rates
|
Oral
Presentation
October 19,
2023
10:30am
(CET)
Room 5
|
About Novavax
Novavax, Inc. (Nasdaq: NVAX)
promotes improved health by discovering, developing and
commercializing innovative vaccines too help protect against
serious infectious diseases. Novavax, a global company based in
Gaithersburg, Md., U.S., offers a
differentiated vaccine platform that combines a recombinant protein
approach, innovative nanoparticle technology and Novavax's patented
Matrix-M adjuvant to enhance the immune response. Focused on the
world's most urgent health challenges, Novavax is currently
evaluating vaccines for COVID-19, influenza, and COVID-19 and
influenza combined. Please visit novavax.com and LinkedIn for
more information.
Contacts:
Investors
Erika Schultz
240-268-2022
ir@novavax.com
Media
Ali Chartan
240-720-7804
media@novavax.com
Logo -
https://mma.prnewswire.com/media/1506866/Novavax_High_Res_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/novavax-advances-science-supporting-protein-based-vaccine-technology-at-idweek-2023-and-world-vaccine-congress-europe-2023-301952812.html